- Home
- LWLG vs DSGN Comparison
LWLG vs DSGN Comparison
Compare LWLG & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LWLG
- DSGN
- Stock Information
- Founded
- LWLG 1991
- DSGN 2017
- Country
- LWLG United States
- DSGN United States
- Employees
- LWLG N/A
- DSGN N/A
- Industry
- LWLG Containers/Packaging
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- LWLG Industrials
- DSGN Health Care
- Exchange
- LWLG Nasdaq
- DSGN Nasdaq
- Market Cap
- LWLG 320.6M
- DSGN 353.9M
- IPO Year
- LWLG N/A
- DSGN 2021
- Fundamental
- Price
- LWLG $1.93
- DSGN $6.01
- Analyst Decision
- LWLG
- DSGN Hold
- Analyst Count
- LWLG 0
- DSGN 3
- Target Price
- LWLG N/A
- DSGN $7.00
- AVG Volume (30 Days)
- LWLG 1.1M
- DSGN 162.3K
- Earning Date
- LWLG 11-13-2024
- DSGN 11-07-2024
- Dividend Yield
- LWLG N/A
- DSGN N/A
- EPS Growth
- LWLG N/A
- DSGN N/A
- EPS
- LWLG N/A
- DSGN N/A
- Revenue
- LWLG $113,190.00
- DSGN N/A
- Revenue This Year
- LWLG N/A
- DSGN N/A
- Revenue Next Year
- LWLG N/A
- DSGN N/A
- P/E Ratio
- LWLG N/A
- DSGN N/A
- Revenue Growth
- LWLG N/A
- DSGN N/A
- 52 Week Low
- LWLG $1.75
- DSGN $2.25
- 52 Week High
- LWLG $5.69
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- LWLG 35.07
- DSGN 51.81
- Support Level
- LWLG $1.75
- DSGN $5.16
- Resistance Level
- LWLG $2.42
- DSGN $6.43
- Average True Range (ATR)
- LWLG 0.26
- DSGN 0.50
- MACD
- LWLG -0.06
- DSGN -0.03
- Stochastic Oscillator
- LWLG 14.63
- DSGN 56.08
About LWLG Lightwave Logic Inc.
Lightwave Logic Inc is a United States-based development stage company moving toward commercialization of next-generation electro-optic photonic devices made on its P2IC technology platform which uses in-house proprietary high-activity and high-stability organic polymers. Electro-optical devices convert data from electric signals into optical signals for multiple applications. It designs and synthesizes organic chromophores for use in its own proprietary electro-optic polymer systems and photonic device designs.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.